Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary ...
Zacks Investment Research on MSN
Is Invesco Biotechnology & Genome ETF (PBE) a strong ETF right now?
Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund launched on 06/23/2005. What Are ...
Buffett’s casino comments raise an uncomfortable truth. Is biotechnology an investment, or is it more of a gambling casino? The honest answer is that it can be either.
Scientists at the Department of Energy's Oak Ridge National Laboratory have created a platform that pinpoints genetic ...
"Biotechnology" is a term commonly applied to the development of new medicines and therapies, the development of genetically modified plants, biofuels, biological treatment, or the production of ...
UC Santa Cruz deepens industry engagement to underscore its vital role in contributing basic research and tomorrow’s talent, convening its first international RNA biotech conference on August 18 ...
Microbial biotechnology is a dynamic field, The origins of microbiology can be traced back to the pioneering research by scientists such as Louis Pasteur and Robert Koch in the 19 th century. Within a ...
Central Carolina Community College alumni working in the biotechnology industry took center stage at a recent biotechnology networking event held at the Dennis A. Wicker Civic & Conference Center in ...
Operator: Hello and welcome to Vir Biotechnology's Second Quarter 2026 Financial Results and Corporate Update Conference Call. As a reminder, this call is being recorded. [Operator Instructions] I ...
The Business & Financial Times on MSN
Financial security (FinSec) series with Dr Philip Takyi: NASDAQ 2026: The dawn of a new capital markets era as technology, biotechnology and quantum innovation redefine Wall Street
Please keep comments respectful. Use plain English for our global readership and avoid using phrasing that could be misinterpreted as offensive. By commenting, you agree to abide by our community ...
IASO Biotechnology ('IASO Bio) today announced the completion of its acquisition of MediSix Therapeutics ('MediSix'), a Singapore-based immune cell engineering and cell therapy company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results